Epidermal growth factor receptor and variant III targeted immunotherapy

Kendra L. Congdon, Patrick C. Gedeon, Carter M. Suryadevara, Hillary G. Caruso, Laurence J.N. Cooper, Amy B. Heimberger, John H. Sampson

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations

Abstract

Immunotherapeutic approaches to cancer have shown remarkable promise. A critical barrier to successfully executing such immune-mediated interventions is the selection of safe yet immunogenic targets. As patient deaths have occurred when tumor-associated antigens shared by normal tissue have been targeted by strong cellular immunotherapeutic platforms, route of delivery, target selection and the immune-mediated approach undertaken must work together to maximize efficacy with safety. Selected tumor-specific targets can spare potential toxicity to normal tissue; however, they are far less common than tumor-associated antigens and may not be present on all patients. In the context of immunotherapy for high-grade glioma, 2 of the most prominently studied antigens are the tumor-associated epidermal growth factor receptor and its tumor-specific genetic deletion variant III. In this review, we will summarize the immune-mediated strategies employed against these targets as well as the caveats particular to these approaches.

Original languageEnglish (US)
Pages (from-to)viii20-viii25
JournalNeuro-oncology
Volume16
DOIs
StatePublished - Sep 12 2014

Keywords

  • epidermal growth factor receptor
  • glioma
  • immunology
  • immunotherapy

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Epidermal growth factor receptor and variant III targeted immunotherapy'. Together they form a unique fingerprint.

Cite this